PPARGC1A and chronic kidney disease: In summary, the AMPK/SIRT1/PGC‐1α pathway serves as a central hub integrating multiple pathological processes in CKD (inflammation, fibrosis, and metabolic dysregulation), making it a highly promising therapeutic target.